Getagraph.com logo
NASDAQ Composite: ( 0.267%) 16 346
S&P 500 Futures
(0.30%) 5 254.75 points
Dow Jones Futures
(0.24%) 39 631 points
Nasdaq Futures
(0.38%) 18 283 points
Oil
(0.79%) $79.89
Gas
(0.52%) $2.31
Gold
(1.74%) $2 381.00
Silver
(1.78%) $28.87
Platinum
(0.96%) $1 000.30
USD/EUR
(0.05%) $0.928
USD/NOK
(-0.40%) $10.82
USD/GBP
(-0.04%) $0.798
USD/RUB
(-0.25%) $92.32

Realtime updates for Autolus Therapeutics PLC [AUTL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Upcoming Earnings Alert

4 days till quarter result
(bmo 2024-05-14)

Expected move: +/- 11.43%

BUY
71.43%
return 14.35%
SELL
28.57%
return 1.74%
Last Updated9 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

1.46% $ 4.17

SELL 123287 min ago

@ $7.30

Issued: 14 Feb 2024 @ 15:45

Return: -42.84%

Previous signal: Feb 14 - 12:33

Previous signal: Buy

Return: 4.66 %

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 16:00):
Profile picture for Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma...

Stats
Today's Volume 886 334
Average Volume 1.68M
Market Cap 726.00M
EPS $0 ( 2024-03-14 )
Next earnings date ( $-0.100 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.47
ATR14 $0.00600 (0.14%)

Volume Correlation

Long: 0.07 (neutral)
Short: -0.44 (neutral)
Signal:(43.75) Neutral

Autolus Therapeutics PLC Correlation

10 Most Positive Correlations
PBTS0.943
OP0.94
FLGC0.938
FNCH0.922
NNOX0.919
ALBO0.916
WKSP0.915
POWL0.912
NBSE0.91
DMRC0.907
10 Most Negative Correlations
PRAA-0.919
RMRM-0.908
DTEA-0.879
AVID-0.875
FCCO-0.873
PINC-0.863
IEP-0.856
PEBK-0.854
PARA-0.853
TUEM-0.851

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Autolus Therapeutics PLC Correlation - Currency/Commodity

The country flag 0.09
( neutral )
The country flag 0.21
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.26
( neutral )
The country flag -0.16
( neutral )

Autolus Therapeutics PLC Financials

Annual 2023
Revenue: $1.70M
Gross Profit: $-4.87M (-286.63 %)
EPS: $-1.200
FY 2023
Revenue: $1.70M
Gross Profit: $-4.87M (-286.63 %)
EPS: $-1.200
FY 2022
Revenue: $6.19M
Gross Profit: $-131.03M (-2 115.37 %)
EPS: $-1.570
FY 2021
Revenue: $2.33M
Gross Profit: $0.00 (0.00 %)
EPS: $-1.970

Financial Reports:

No articles found.

Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators